Contrasting Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) & DexCom (NASDAQ:DXCM)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and DexCom’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
DexCom	17.22%	31.40%	10.58%

Analyst Ratings

This is a breakdown of current recommendations for Health Sciences Acquisitions Co. 2 and DexCom, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00
DexCom	0	4	12	2	2.89

DexCom has a consensus target price of $99.29, indicating a potential upside of 11.88%. Given DexCom’s stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Health Sciences Acquisitions Co. 2.

Insider and Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Earnings & Valuation

This table compares Health Sciences Acquisitions Co. 2 and DexCom”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
DexCom	$3.62 billion	9.57	$541.50 million	$1.67	53.14

DexCom has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Summary

DexCom beats Health Sciences Acquisitions Co. 2 on 11 of the 12 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.